IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis
Authors
Keywords
Low-grade glioma, IDH wild-type, Diffuse glioma, Isocitrate dehydrogenase
Journal
NEUROSURGICAL REVIEW
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-26
DOI
10.1007/s10143-018-0996-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas
- (2018) Gaëtan Poulen et al. JOURNAL OF NEUROSURGERY
- IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas
- (2017) Olatz Etxaniz et al. JOURNAL OF NEURO-ONCOLOGY
- IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas
- (2017) Amélie Darlix et al. JOURNAL OF NEURO-ONCOLOGY
- The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma
- (2017) Ryan S. Youland et al. JOURNAL OF NEURO-ONCOLOGY
- Adult IDH wild-type lower-grade gliomas should be further stratified
- (2017) Abudumijit Aibaidula et al. NEURO-ONCOLOGY
- The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis
- (2017) Maarten M J Wijnenga et al. NEURO-ONCOLOGY
- The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas
- (2017) Toral Patel et al. NEUROSURGERY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Brigitta G Baumert et al. LANCET ONCOLOGY
- Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide
- (2016) Michael Wahl et al. NEURO-ONCOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Value of Early Postoperative FLAIR Volume Dynamic in Glioma with No or Minimal Enhancement
- (2016) Stefanie Bette et al. World Neurosurgery
- Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma – A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy
- (2016) Roland Roelz et al. Scientific Reports
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
- (2015) Adriana Olar et al. ACTA NEUROPATHOLOGICA
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
- (2015) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma
- (2015) Kazuhiro Tanaka et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424
- (2015) Barbara J. Fisher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases
- (2015) Chao Tang et al. JOURNAL OF NEURO-ONCOLOGY
- IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy
- (2015) Yasuo Iwadate et al. JOURNAL OF NEURO-ONCOLOGY
- Influence of 1p19q status and Ki67 index to predict extent of resection in WHO grade II gliomas: a virtual patient model
- (2015) Dominik Cordier et al. JOURNAL OF NEURO-ONCOLOGY
- Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas
- (2015) Ming-Yang Li et al. PLoS One
- IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status
- (2015) Jacqueline Kessler et al. RADIOTHERAPY AND ONCOLOGY
- IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma
- (2015) Ailiang Zeng et al. Oncotarget
- IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
- (2015) Heather E. Leeper et al. Oncotarget
- Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas
- (2015) Mueez Waqar et al. World Neurosurgery
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
- (2014) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- Commentary on IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas
- (2014) Gianluca Marucci EPILEPSIA
- A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers
- (2014) Dominik Cordier et al. JOURNAL OF NEURO-ONCOLOGY
- Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas
- (2014) C. Goze et al. NEURO-ONCOLOGY
- The “onco-functional balance” in surgery for diffuse low-grade glioma: integrating the extent of resection with quality of life
- (2013) Hugues Duffau et al. ACTA NEUROCHIRURGICA
- An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
- (2013) Marzena Anna Lewandowska et al. Molecular Diagnosis & Therapy
- IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
- (2012) YOSHIKO OKITA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis
- (2012) Philip C. De Witt Hamer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
- (2012) Rezvan Ahmadi et al. JOURNAL OF NEURO-ONCOLOGY
- Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients
- (2012) Tamara Ius et al. JOURNAL OF NEUROSURGERY
- Glutamate is associated with a higher risk of seizures in patients with gliomas
- (2012) T. I. Yuen et al. NEUROLOGY
- IDH1 mutation of gliomas with long-term survival analysis
- (2012) JAE KYUNG MYUNG et al. ONCOLOGY REPORTS
- Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients
- (2012) Xiaohui Ren et al. PLoS One
- IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival
- (2011) Niklas Thon et al. CANCER
- Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
- (2011) Akitake Mukasa et al. CANCER SCIENCE
- Low-grade gliomas in adults
- (2011) Nader Sanai et al. JOURNAL OF NEUROSURGERY
- Natural history and surgical management of incidentally discovered low-grade gliomas
- (2011) Matthew B. Potts et al. JOURNAL OF NEUROSURGERY
- Histomolecular classification of adult diffuse gliomas: The diagnostic value of immunohistochemical markers
- (2011) D. Figarella-Branger et al. REVUE NEUROLOGIQUE
- Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis
- (2010) Philippe Metellus et al. ACTA NEUROPATHOLOGICA
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- Glutamate and the biology of gliomas
- (2010) John de Groot et al. GLIA
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- Review of current microsurgical management of insular gliomas
- (2009) Francesco Signorelli et al. ACTA NEUROCHIRURGICA
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
- (2009) S. Nobusawa et al. CLINICAL CANCER RESEARCH
- A personal consecutive series of surgically treated 51 cases of insular WHO Grade II glioma: advances and limitations
- (2009) Hugues Duffau JOURNAL OF NEUROSURGERY
- Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
- (2009) Linda Douw et al. LANCET NEUROLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Late neurocognitive decline after radiotherapy for low-grade glioma
- (2009) Mustafa Khasraw et al. Nature Reviews Neurology
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm
- (2008) Emmanuel Mandonnet et al. NEUROSURGICAL REVIEW
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started